CURE.AX vs. BANK.AX
CURE.AX (Global X S&P Biotech ETF) and BANK.AX (Global X Australian Bank Credit ETF) are both exchange-traded funds - CURE.AX is a Health & Biotech Equities fund tracking the S&P Biotechnology Select Industry Index, while BANK.AX is a Corporate Bonds fund tracking the Solactive Australian Bank Credit Index. Both are passively managed. Over the past year, CURE.AX returned 65.69% vs 4.33% for BANK.AX. At a 0.16 correlation, their price movements are largely independent. CURE.AX charges 0.45%/yr vs 0.25%/yr for BANK.AX.
Performance
CURE.AX vs. BANK.AX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CURE.AX achieves a 22.66% return, which is significantly higher than BANK.AX's 2.36% return.
CURE.AX
- 1D
- 0.58%
- 1M
- 17.05%
- 6M
- 20.39%
- YTD
- 22.66%
- 1Y
- 65.69%
- 3Y*
- 21.60%
- 5Y*
- 5.62%
- 10Y*
- —
BANK.AX
- 1D
- 0.10%
- 1M
- 0.71%
- 6M
- 2.05%
- YTD
- 2.36%
- 1Y
- 4.33%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
CURE.AX vs. BANK.AX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
CURE.AX Global X S&P Biotech ETF | 22.66% | 25.25% | 0.04% |
BANK.AX Global X Australian Bank Credit ETF | 2.36% | 4.39% | 2.23% |
Correlation
The correlation between CURE.AX and BANK.AX is 0.24, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.24 |
Correlation (All Time) Calculated using the full available price history since Jul 22, 2024 | 0.16 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CURE.AX vs. BANK.AX — Risk / Return Rank
CURE.AX
BANK.AX
CURE.AX vs. BANK.AX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Global X S&P Biotech ETF (CURE.AX) and Global X Australian Bank Credit ETF (BANK.AX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CURE.AX | BANK.AX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.58 | ||
| Sortino ratioReturn per unit of downside risk | +0.30 | ||
| Omega ratioGain probability vs. loss probability | 1.43 | 1.43 | 0.00 |
| Calmar ratioReturn relative to maximum drawdown | 5.80 | 3.83 | +1.96 |
| Martin ratioReturn relative to average drawdown | 14.61 | 12.35 | +2.26 |
Loading charts...
Drawdowns
CURE.AX vs. BANK.AX - Drawdown Comparison
The maximum CURE.AX drawdown since its inception was -59.81%, which is greater than BANK.AX's maximum drawdown of -1.60%. Use the drawdown chart below to compare losses from any high point for CURE.AX and BANK.AX.
Loading charts...
Drawdown Indicators
| CURE.AX | BANK.AX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -59.81% | -1.60% | -58.21% |
Max Drawdown (1Y)Largest decline over 1 year | -11.68% | -1.10% | -10.58% |
Max Drawdown (3Y)Largest decline over 3 years | -28.37% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -50.92% | — | — |
Current DrawdownCurrent decline from peak | -5.45% | -0.20% | -5.25% |
Average DrawdownAverage peak-to-trough decline | -27.38% | -0.19% | -27.19% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.66% | 0.35% | +4.31% |
Volatility
CURE.AX vs. BANK.AX - Volatility Comparison
Global X S&P Biotech ETF (CURE.AX) has a higher volatility of 9.67% compared to Global X Australian Bank Credit ETF (BANK.AX) at 0.48%. This indicates that CURE.AX's price experiences larger fluctuations and is considered to be riskier than BANK.AX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CURE.AX | BANK.AX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.67% | 0.48% | +9.19% |
Volatility (6M)Calculated over the trailing 6-month period | 21.01% | 1.48% | +19.53% |
Volatility (1Y)Calculated over the trailing 1-year period | 25.95% | 2.06% | +23.89% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 30.91% | 2.45% | +28.46% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 31.70% | 2.45% | +29.25% |
CURE.AX vs. BANK.AX - Expense Ratio Comparison
CURE.AX has a 0.45% expense ratio, which is higher than BANK.AX's 0.25% expense ratio.
Dividends
CURE.AX vs. BANK.AX - Dividend Comparison
CURE.AX has not paid dividends to shareholders, while BANK.AX's dividend yield for the trailing twelve months is around 5.10%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
BANK.AX Global X Australian Bank Credit ETF | 5.10% | 5.31% | 1.61% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
CURE.AX Global X S&P Biotech ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.06% | 11.64% | 9.47% | 2.05% |
Frequently Asked Questions
CURE.AX and BANK.AX have a correlation of 0.24, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, BANK.AX is cheaper at 0.25% per year. The better choice depends on whether you care most about return, fees, risk, or income.
BANK.AX is cheaper with a 0.25% expense ratio, compared with 0.45% for CURE.AX.
CURE.AX is categorized as Health & Biotech Equities, while BANK.AX is Corporate Bonds. CURE.AX tracks S&P Biotechnology Select Industry Index, while BANK.AX tracks Solactive Australian Bank Credit Index. Their fees differ too: 0.45% for CURE.AX and 0.25% for BANK.AX.
Find the right allocation for CURE.AX and BANK.AX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer